lactobacillus gasseri (BGP345A) / BioGaia - LARVOL DELTA

OIC1: Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications (clinicaltrials.gov) - P2 | N=14 | Completed | Sponsor: BioGaia Pharma AB | Recruiting ➔ Completed | N=126 ➔ 14 | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Constipation • Gastroenterology • Gastrointestinal Disorder • Oncology • Pain

Therapeutic Value of Lactobacillus gasseri 345A in Chronic Constipation. (PubMed, Neurogastroenterol Motil) - "Treatment with Lactobacillus gasseri can alleviate pain sensations in functional constipation, possibly with an improved bowel-emptying function."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder • Pain • TRPV1

OIC1: Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications (clinicaltrials.gov) - P2 | N=126 | Recruiting | Sponsor: BioGaia Pharma AB | Trial completion date: Jan 2023 ➔ Dec 2023 | Trial primary completion date: Jan 2023 ➔ Dec 2023

Trial completion date • Trial primary completion date • Constipation • Gastroenterology • Gastrointestinal Disorder • Oncology • Pain

OIC1: Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications (clinicaltrials.gov) - P2; N=126; Recruiting; Sponsor: BioGaia Pharma AB

Clinical • New P2 trial • Constipation • Gastroenterology • Gastrointestinal Disorder • Oncology • Pain